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acute care utilization in MF TD patients. Potential short term and long term benefits 
of ICT in MF need to be validated in prospective clinical trials.
PSY11
The ePidemiologY of gaucher diSeaSea comPrehenSive review of The 
liTeraTure
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Objectives: Gaucher disease (GD) is a rare genetic disorder characterized by the 
accumulation of lipid glucosylceramide in organs such as the spleen, liver and bone 
marrow. Based operationally on the presence and severity of central nervous system 
manifestations, GD is classified into three types (GD1, GD2, and GD3), although GD1 
is the predominant type diagnosed in most regions. However, the epidemiology of 
GD is not well established. MethOds: A comprehensive review of English language 
literature primarily focusing on the incidence and prevalence of GD was performed. 
Literature indexed in MEDLINE, EMBASE, and CENTRAL and published between 
January 1990 and February 2013 was searched. “Grey literature” sources from key 
congresses were also searched. Results: 22 studies of the epidemiology of GD 
from North America, Europe, Israel, Australia, and Japan were identified. Nine stud-
ies estimated prevalence of GD in the general population at 0.33–1.75 per 100,000. 
The prevalence was higher in populations of Ashkenazi Jewish descent, ranging 
from 82.8–222.2 per 100,000. Seven studies reported GD incidence using a general 
population, while one study screened Ashkenazi Jews to identify carrier couples 
of GD mutations in Israel. The incidence of GD varied among studies performed in 
the general population from 0.30–5.80 per 100,000. The highest incidence rate was 
reported in Austria, where newborns were prospectively screened for mutations in 
the cognate GBA1 gene, thus likely increasing the cases diagnosed in this popula-
tion. The estimated carrier frequency of four GBA mutations among individuals of 
Ashkenazi Jewish descent was 5.7%, and the frequency of affected fetuses in carrier 
couples who underwent prenatal diagnosis was 23.5%. cOnclusiOns: GD is a rare 
disorder that disproportionately affects individuals of Ashkenazi Jewish descent. 
The observed variability of GD incidence and prevalence may be explained by dif-
ferences in the studied population, region, study design, and diagnostic criteria.
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Objectives: To estimate the safety and tolerability of azacitidine in those suffer-
ing from intermediate-2 and high risk Myelodysplastic Syndromes (MDS), in a real 
world setting in Greece. MethOds: A nationwide, retrospective chart review study 
was conducted, based on 17 Hematology departments of Hospitals throughout the 
country. Eligible patients were analyzed concerning the frequency of Serious and 
Non-Serious-Adverse Drug Reactions (SADRs/NSADRs). By definition, a SADR could 
result death, life-threatening condition, significant disability, requires hospitaliza-
tion or might be considered medically important. Any reaction which does not 
fulfill the above description is a NSADR. Patients were recruited if were > 18 years 
and were alive at the time of their data collection, they have completed at least one 
evaluation after azacitidine treatment initiation and at least one cycle of azacitidine 
treatment regardless of the outcome. The study was conducted in accordance with 
the declaration of Helsinki. Results: The incidence of NSADRs and SADR during 
treatment was 50% and 42%, respectively. The most commonly reported NSADRs 
were neutropenia (11.4%), thrombocytopenia (9.1%), pyrexia (8.0%) and constipation 
(8.0%). Regarding their intensity, 45.7% of NSADRs were grade I, 43.6% were grade 
II, and 10.6% were grade III. None of the NSADRs resulted in patient hospitaliza-
tion. The most commonly reported SADRs were thrombocytopenia (13.6%), pyrexia 
(10.2%), neutropenia (9.1%), febrile neutropenia (4.5%), anaemia and respiratory tract 
infection (both 4.5%). 48.6% of all SADRs were grade III,while 18% were grade IV. In 
20.8% of SARDs no action was taken, 1.4% resulted in permanent discontinuation, 
while temporary treatment interruption was required for 34.7% of patients. 30.7% of 
patients experienced any SADRs, required hospitalization. cOnclusiOns: In this 
study, the safety and tolerability of azacitidine for intermediate-2 and high risk MDS 
patients was descriptively analyzed based on Greek data. A broader, real life, analysis 
is needed to reach more decisive conclusions in the local setting.
SYSTemic diSorderS/condiTionS – cost Studies
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Objectives: British Columbia (BC) currently performs around 250 bariatric pro-
cedures annually. The number of individuals eligible for bariatric surgery in BC is 
approximately 87,000 and is increasing at about 1.04% annually. Obese individuals 
are high volume users of the health care system and bariatric surgery has proven to 
be an effective intervention for weight loss and for reducing the impact of obesity-
related disease. The objective of this study was to determine the budget impact of 
increasing the volume of bariatric procedures performed in BC to include 1% of all 
eligible patients each year. MethOds: A budget impact model accounting only 
for direct health care costs was created using data from Statistics Canada, peer-
reviewed literature, the Canadian Institute for Health Information and case-costing 
Objectives: Immune (idiopathic) thrombocytopenia (ITP) is an autoimmune 
condition characterized by increased platelet destruction and suboptimal platelet 
production, resulting in low platelet counts (thrombocytopenia). Romiplostim has 
shown efficacy in increasing platelet counts. The objective of this study was to 
conduct meta-analysis and present total evidence for Romiplostim for treatment 
of ITP. MethOds: For this meta-analysis we included randomized controlled tri-
als (RCTs) evaluating Romiplostim for the treatment of ITP. We included RCTs that 
compared romiplostim versus placebo for management of ITP, had a treatment 
duration of at least 24 weeks, were doubleblind (patients and investigators blinded) 
and reported data on platelet response. A systematic literature search for Etanercept 
trials was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, 
and Cochrane. Data was collected for the study size, interventions, year, and the 
two outcomes overall and durable platelet response rate. For meta-analysis, random 
effects and fixed effects models were used to obtain cumulative statistics. Results: 
Two RCTs with a total of 125 patients were identified. The pooled response rates 
for Romiplostim for overall platelet response rate were 82% (95% CI 73%-90%); and 
for durable platelet response rate were 48% (95% CI 26%-71%). The pooled response 
rates for placebo for overall platelet response rate were 7% (95% CI 0%-15%), and for 
durable platelet response rate were 2% (95% CI 0%-4%). For overall platelet response 
rate the cumulative relative risk with placebo versus Romiplostim was 0.09 (95% CI 
4%-14%). For durable platelet response rate, the cumulative relative risk with placebo 
versus Romiplostim was 0.03 (95% CI 0%-6%). cOnclusiOns: Meta-analysis shows 
Romiplostim offers patients with Immune idiopathic thrombocytopenia an effective 
therapeutic option for increasing platelet counts.
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Objectives: Obinutuzumab (GA101) is a novel, glycoengineered, type II CD20 anti-
body. In the phase 3 CLL11 trial, chlorambucil (Clb) plus GA101 (G-Clb) significantly 
prolonged progression-free survival (PFS) compared with either Clb alone or rituxi-
mab plus Clb in previously untreated patients with chronic lymphocytic leukemia 
(CLL) and comorbidities. We present indirect treatment comparisons (ITCs) of G-Clb 
versus bendamustine (Benda), and ofatumumab plus Clb (Ofat-Clb). MethOds: We 
conducted a systematic review of non-randomized and randomized controlled trials 
(RCTs) to assess the clinical efficacy and safety of pharmacological interventions 
for previously untreated CLL; manuscripts (Jan 1992 to Mar 2013), abstracts (includ-
ing hand-searching; Jan 2010 to Mar 2013), and in-progress trials were screened for 
inclusion. Based on extracted data, a feasibility assessment of quantitative analysis 
was undertaken. ITCs of G-Clb versus Benda and G-Clb versus Ofat-Clb were derived. 
The WinBUGS code used to parameterize the fixed-effect network meta-analysis 
model used a natural logarithm of the hazard ratios (HR) for PFS as the (continuous) 
outcome variable. Results: Of the 4,819 publications identified, 262 manuscripts 
and 13 abstracts were selected for detailed evaluation. Following de-duplication of 
publications, the data set included 28 RCTs (157 publications) and nine non-RCTs 
(14 publications). ITCs were based on HR and 95% confidence intervals (CIs) reported 
for G-Clb in the CLL11 trial, for Benda in the Knauf et al. publications, and for Ofat-
Clb in the Complement 1 trial. The ITC for G-Clb versus Benda had a HR (95% CI) 
of 0.53 (0.35-0.77) and the ITC for G-Clb versus Ofat-Clb had a HR (95% CI) of 0.33 
(0.22-0.47). cOnclusiOns: Based on the ITCs of available evidence in this indica-
tion, G-Clb is expected to improve PFS rates compared with Benda or Ofat-Clb. How 
this benefit will translate into overall survival differences will be assessed when the 
available data are more mature.
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Objectives: To compare incidence of myelofibrosis (MF)-related complications and 
all-cause and MF-related resource utilization (RU) in blood transfusion-dependent 
(TD) MF patients treated with vs. without iron-chelating therapy (ICT+ vs. ICT-).  
MethOds: Two commercial health care claims databases, Truven MarketScan 
(2000-2012) and PharMetrics (2001-2012), were analyzed. Patients with ≥ 2 MF ICD-9 
diagnosis codes ≥ 30 days apart and ≥ 18 years at first MF diagnosis were included. 
First evidence of TD (index date) was defined as ≥ 3 transfusion events within any 
3-month period. Adjusted incidence rate ratios (aIRRs) of MF-related complications 
and all-cause and MF-related RU in TD ICT+ vs. ICT- patients were assessed using 
Poisson regressions, controlling for baseline comorbidities and MF-related com-
plications. Results: Of the 571 eligible TD MF patients, 103 (18%) were ICT+ and 
468 (82%) were ICT-. Mean age was similar between groups (ICT+: 67.2[SD: 10.4] 
vs. ICT-: 66.6[11.7]). Mean observation time was longer for ICT+ patients (months, 
22.2[13.9] vs. 12.6[11.6]). ICT- patients had higher mean Charlson Comorbidity Index 
(1.8[1.8] vs. 2.3[2.1]), suggesting a greater burden of comorbidities. Mean number 
of transfusion events/year was similar between groups (22.4[19.5] vs. 22.2[28.5]; 
p= 0.94). ICT+ patients had lower rates of thrombocytopenia (aIRR: 0.54; p< .001) and 
pancytopenia (0.53; p< .001). Rates of other MF-related complications were simi-
lar between groups. ICT+ patients had significantly lower rates of all-cause and 
MF-related ER visits (all-cause aIRR: 0.83 [95% CI: 0.72-0.95]) as well as inpatient stays 
(0.75 [0.64-0.87]) and days (0.52 [0.50-0.55]), but higher rates of outpatient visits (1.22 
[1.19-1.25]). cOnclusiOns: Despite similar complication profiles, ICT+ patients 
had significantly lower rates of acute care, but higher rates of outpatient care vs. 
ICT- patients, suggesting a possible link between closer monitoring and decreased 
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(MCO) due to the severity of the conditions and their minimal budet impact. 
However, as interest by pharmaceutical companies, competition, and spend in the 
orphan drug category grows, payers are likely to look for ways to reduce or con-
tain the cost. This is particularly true among pharmacy benefit products where 
payers have more effective utilization management tools at their disposal when 
compared to medical benefit products. MethOds: This research assessed the 
Wholesale Acquisition Cost (WAC) of all non-oncology FDA designated pharmacy 
benefit orphan drugs that were launched 2004-2014 and plotted these against dis-
ease prevalence. The extent of payer management for these products was deter-
mined for the most common formulary design of 6 MCOs (2 national, 2 regional, and 
2 integrated). Results: Stronger payer management of pharmacy benefit orphan 
drugs has emerged in select conditions where multiple labeled competitors with 
comparable levels of efficacy and material price differences exist, regardless of 
disease prevalence. The most common type of management introduced was either a 
‘preferred product’ or ‘step edit’. Integrated plans introduced stronger management 
more frequently when compared to national and regional plans. cOnclusiOns: 
Given the increased payer spend in the orphan drug category, payers have begun to 
manage products in areas where cost savings can be achieved without sacrificing 
outcomes, irrespective of rare disease prevalence. In disease areas where multiple 
product options do not exist, payer management tended to be minimal, and typically 
only required a confirmation of a disease diagnosis through a Prior Authorization. 
While integrated health systems tend to have the tightest control on orphan prod-
ucts given their close physician relationships, national and regional plans have also 
begun to implement a similar level of control for select products.
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Objectives: To estimate the economic burden of psoriatic patients with varying 
levels of psoriasis severity in the Brazilian Private Health System. MethOds: The 
2012 Brazil National Health and Wellness Survey (NHWS; validated/stored by Kantar 
Health, USA, N= 12,000), a nationally representative health survey conducted among 
adults in Brazil, was used as the data source in this study. All respondents who 
reported a diagnosis of psoriasis severity were included in the analyses (n= 210). 
Economic outcomes (work productivity, health care resource use, and costs) were 
reported by level of psoriasis severity ( n= 157 mild vs. n= 42 moderate vs. n= 11 
severe). To calculate the cost of health care resource use, a structured search was 
performed on MEDLINE database (via PubMed) using the MesH Database terms 
accordance with the following terms ((“Costs and Cost Analysis” [Mesh]) AND 
(“psoriatic” [Mesh]). To calculate the cost of absent days due to health events, a 
human capital approach was used with data retrieved from national labor legisla-
tions and the Brazilian Institute for Geography and Statistics (IBGE) 2013. Results: 
Patients with psoriasis were 50.5% female and had a mean age of 40.8 years. Few 
demographic or health history differences were observed by level of severity (one 
exception was the rate of obesity which increased from 25.5% to 38.1% to 54.5% for 
mild, moderate, and severe, respectively, p< .05). Comparing the total cost (absen-
teeism, presenteeism, provider visits and hospitalization) across levels of severity, 
the cost of severe psoriasis was BRL 224.251, six times the cost of those with mild 
severity (BRL 34.508) and over twice the cost of those with moderate severity (BRL 
79.427). cOnclusiOns: The disease cost is proportional to the level of psoriasis 
severity in the Brazilian Private Health System, suggesting improved disease man-
agement (e.g., improved access to treatments; earlier diagnosis, etc) may alleviate 
substantial societal costs.
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Objectives: CHC is associated with significant economic burden. This 
study evaluated the health care cost alleviation associated with treatment of 
CHC. MethOds: Health insurance claims from 60 self-insured U.S companies 
01/2001-03/2012 were analyzed. Adult patients with ≥ 1 diagnosis claim of CHC 
(ICD-9-CM: 070.44, 070.54), newly initiated on interferon with ≥ 2 dispensings, 
and with more than 48 weeks of follow-up were selected. Patients diagnosed 
with HIV or who completed only 24 weeks of interferon therapy (a surrogate for 
CHC genotypes 2 and 3) were excluded from the study. Interferon users were 
categorized into complete and discontinued therapy cohorts according to their 
adherence to therapy during the first 36 to 48 weeks of treatment. During the post 
48 week period, complete and discontinued therapy cohorts were compared for 
health care resource utilization using rate ratios (RRs), as well as all-cause and 
CHC-related health care costs using per patient per year (PPPY) cost differences. 
Confidence intervals (CI) and p-values for cost differences were calculated using a 
nonparametric bootstrap. Results: A total of 1017 patients with complete and 953 
patients with discontinued interferon therapy were identified. For the complete 
and discontinued therapy cohorts, respectively, mean age was 49.6 and 50.4 years; 
38% were female in both cohorts. Relative to the discontinued therapy cohort, the 
complete therapy cohort had significantly fewer hospitalizations (RR [95% CI]: 
0.74 [0.68;0.81], P< .001) and outpatient visits (RR [95% CI]: 0.92 [0.91;0.93], P< .001), 
which translated into significantly lower total health care costs PPPY (cost differ-
ence [95% CI]: -$4,540 [-7,680; -1,570], P= 0.004). The majority, 61%, of the all-cause 
cost differences between cohorts was not related to CHC. cOnclusiOns: CHC 
patients who have completed an interferon therapy and presumably have higher 
rate of achieving SVR have lower costs post therapy. Interestingly, both non-CHC 
and CHC-related costs were found to be reduced.
and resource utilization data from several Canadian hospitals. The model assumes 
an inflation rate of 2% per annum on future costs. A series of one and multi-way 
sensitivity analyses were performed around a number of parameters using a 
Monte Carlo simulation to establish their influence on model outcomes. Results: 
Bariatric surgery is an expensive procedure estimated at $12,804.81 CAD. It is also 
associated with high pre and post-operative costs that stem from the significant 
support required by health care professionals and the cost of potential surgical 
complications. Comparatively, individuals not receiving surgical intervention (the 
standard of care) also incur a significant amount of health care expenditure caused 
by the high prevalence of multiple chronic and acute conditions within this popu-
lation. The outcomes of the budget impact analysis predict that over 10 years, an 
individual that undergoes bariatric surgery will incur $1,628.73 CAD less in direct 
provincial health care expenditure when compared to an individual receiving the 
standard of care. cOnclusiOns: By increasing the number of bariatric procedures 
performed to 1% of eligible individuals each year, BC could reduce health care spend-
ing by $1,432,937.78 CAD over 10 years.
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Objectives: Cystic fibrosis (CF) is one of 7,000 rare diseases as defined by the 
Food and Drug Administration. Since the Orphan Drug Act of 1983, CF has evolved 
into a successfully treated chronic disease through the development of new thera-
pies. The purpose of this analysis was to estimate the potential budget impact 
of a novel CF therapy, ivacaftor, on hypothetical managed care plans of varying 
size. MethOds: A literature search was conducted in MEDLINE to identify the cur-
rent prevalence and adherence estimates of G551D mutation CF patients treated 
with pharmaceuticals. Additionally, Medi-Span drug knowledge data was used 
to estimate wholesale acquisition cost for ivacaftor. A probabilistic Monte-Carlo 
simulation model was constructed in Microsoft Excel using literature supported 
CF disease prevalence, G551D mutation, patient adherence, and ivacaftor cost 
estimates. The model evaluated iterations of three hypothetical managed care 
plans made up of 500,000 (plan A); 2,000,000 (plan B); and 4,000,000 (plan C) patient 
lives and captured annual projected ivacaftor patients and treatment expendi-
tures. Simulations were conducted a 1000 times to derive confidence intervals 
under each scenario. Results: The model estimated that for health Plan A there 
would be approximately 1.67 treated patients (95% confidence interval (CI): 1.55-
1.80) with annual expenditures of $334,476 (95% CI: $306,817-$362,136); Plan B 
treated 6.52 patients (95% CI: 6.05-6.99) with annual expenditures of $1,270,713 
(95% CI: 1,169,781-1,371,645); Plan C treated 13.37 patients (95% CI: 12.39-14.36) 
with annual expenditures of $2,631,001 (CI: $2,419,785-$2,842,217). The per mem-
ber per month increase in premiums to cover this new expense was estimated to 
be $0.05. cOnclusiOns: New therapies for rare conditions, such as ivacaftor, can 
have a substantial impact on the overall budget of a health plan even though only 
a small number of patients are treated. The high annual cost of ivacaftor translates 
to a sizeable increase in the pharmacy PMPM.
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Objectives: One third of children and adolescents in the United States are 
overweight and over 18% are obese. Childhood obesity has been associated with 
increased morbidity in childhood and frequent tracking into adulthood. Weight-
loss surgery has recently become an accepted treatment for severe adolescent 
obesity. We have constructed a microsimulation to quantify potential savings 
in lifetime (age 18 to 80) medical costs after obese adolescents undergo Roux-
en-Y gastric bypass surgery. MethOds: Published literature and data from the 
2004 – 2010 rounds of the Medical Expenditure Panel Survey (MEPS) were used 
to inform health state costs and transition probabilities. Surgical complication 
rates are included and the costs of these complications are estimated using 
Medicare reimbursement rates and the AHRQ HCUP National Inpatient Sample 
Query Tool. Results: The costs of complications ranged from $120 to $16,900, 
but the complications only occurred in 0.2% to 1.3% of patients. Without the cost 
of the initial procedure, we find the present value (discounted 3% annually) of 
reductions in lifetime medical expenditures for an 18 year-old male with a BMI 
of ≥ 40 to be between $19,535 and $13,073, if his post-operative BMI is between 25 
and 30, respectively. The present values of these savings for females are between 
$20,446 and $13,851. All of these savings are statistically greater than zero (P < 
0.001). However, because the prevalence of extremely high BMI is rare, the costs 
assigned to individuals with BMI ≥ 40 are most representative of individuals with 
a BMI near 40. Savings from the treatment of more extreme obesity are likely 
greater. cOnclusiOns: Given that the cost of Roux-en-Y gastric bypass surgery 
for adults can range from $20,000 to $30,000, our results indicate that this sur-
gery is likely not cost-saving for the majority of obese adolescents. However, the 
procedure may still be cost-effective, depending on quality-of-life improvements.
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Objectives: In the US, orphan drugs for rare diseases have historically been able 
to achieve favorable price and access on formularies of Managed Care Organization 
